Harvard University & Astella Pharma Inc. have inked an agreement for three years for a strategic research alliance to be able to support several multi-year research projects, that have been started by the faculty at the University, and mainly focused on research and development of new technologies and novel therapeutics of similar interest.
Apparently, the alliance will be providing important support to the joint research efforts in the future wherein the academic laboratories will be returning to regular activities after the major disruptions caused by the COVID-19 pandemic over.
Astellas, as per the new alliance, will be issuing one or more challenges that will be based on the research scopes of Astellas to inspire the research proposals by Harvard faculty. A number of those proposals will be further chosen by Astellas for the funding of the project basing it on the firm’s scientific rationale as well as a projected impact on the value for patients.
The projects will be spanning over various ranges of development stages, beginning from the initial investigations of the biological mechanisms of a disease, towards the identification of potential therapeutic targets, or even to the validation and generation of newer therapeutic entities.
Harvard Office of Technology Development’s Managing Director of Strategic Partnerships, Vivian Berlin stated that the academic-industry partnership is essential for the advancement of biomedical discovery as well as confirmation that promising newer therapies are to be developed at their complete potential.
Berlin further said that the research alliance with Astellas shall provide key funding to all the Harvard labs and also expand their scientific community of different partners that will help progress the human medicine and health amid major challenges. Alliances such as this help escalate creativity while also driving quick innovation to benefit all the patients in need.
The projects may get selected from different labs at Harvard University and the request for the proposal shall be circulated extensively. Both Harvard and Astellas are focused on their efforts to explore collaborative research opportunities amid challenging times.